Alexion Pharmaceuticals, Inc. (ALXN) Shares Bought by State of Alaska Department of Revenue

State of Alaska Department of Revenue boosted its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 2.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 40,103 shares of the biopharmaceutical company’s stock after buying an additional 863 shares during the period. State of Alaska Department of Revenue’s holdings in Alexion Pharmaceuticals were worth $5,573,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. FMR LLC lifted its stake in Alexion Pharmaceuticals by 1.2% during the second quarter. FMR LLC now owns 19,515,617 shares of the biopharmaceutical company’s stock worth $2,422,865,000 after purchasing an additional 225,688 shares during the last quarter. Northern Trust Corp lifted its stake in Alexion Pharmaceuticals by 0.7% during the second quarter. Northern Trust Corp now owns 2,867,981 shares of the biopharmaceutical company’s stock worth $356,060,000 after purchasing an additional 19,984 shares during the last quarter. Iridian Asset Management LLC CT lifted its stake in Alexion Pharmaceuticals by 14,950.7% during the second quarter. Iridian Asset Management LLC CT now owns 1,496,192 shares of the biopharmaceutical company’s stock worth $185,752,000 after purchasing an additional 1,486,251 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Alexion Pharmaceuticals by 13.6% during the second quarter. Wells Fargo & Company MN now owns 1,485,735 shares of the biopharmaceutical company’s stock worth $184,454,000 after purchasing an additional 178,018 shares during the last quarter. Finally, Putnam Investments LLC lifted its stake in Alexion Pharmaceuticals by 58.4% during the second quarter. Putnam Investments LLC now owns 1,160,859 shares of the biopharmaceutical company’s stock worth $144,120,000 after purchasing an additional 428,033 shares during the last quarter. 93.06% of the stock is owned by institutional investors.

NASDAQ ALXN opened at $121.94 on Friday. Alexion Pharmaceuticals, Inc. has a 1-year low of $102.10 and a 1-year high of $144.91. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.72 and a quick ratio of 2.27. The stock has a market capitalization of $30.98 billion, a PE ratio of 23.63, a P/E/G ratio of 1.27 and a beta of 0.79.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.58. Alexion Pharmaceuticals had a positive return on equity of 15.21% and a negative net margin of 2.68%. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $976.81 million. During the same quarter in the previous year, the company posted $1.56 EPS. Alexion Pharmaceuticals’s revenue for the quarter was up 14.5% on a year-over-year basis. Equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.45 earnings per share for the current year.

ALXN has been the subject of several research analyst reports. Zacks Investment Research lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 13th. Barclays lifted their price target on Alexion Pharmaceuticals to $175.00 and gave the stock an “overweight” rating in a research note on Friday, September 28th. Stifel Nicolaus lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price target for the stock from $154.00 to $130.00 in a research note on Tuesday, August 7th. JPMorgan Chase & Co. lifted their price target on Alexion Pharmaceuticals from $184.00 to $188.00 and gave the stock an “overweight” rating in a research note on Friday, July 27th. Finally, ValuEngine lowered Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $160.74.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Featured Story: New Google Finance Tool and Screening Stocks

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply